RxDoctor Payments Data

Tony Ku, MD

Pain Medicine · Paoli, PANPI 1346283637

Payments from drug & device makers

$599in general payments, 2019–2025

Across 21 payments — averaging $28.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Curonix LLC$305
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$136
  • Nevro Corp.$40
  • Amarin Pharma, Inc.$23
  • Vertex$20
  • Orexo US, Inc.$17
  • plus $57 from 4 others

What the payments were for

  • Travel & lodging$28948%
  • Food & beverage$30952%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$599 in reported general payments places this provider in the 30th percentile of 294 pain medicine providers in Pennsylvania.

See all pain medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$65,559
Medicare patients
95
Services billed
4,029

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxycontinOxycodone Hcl61$45,024
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl169$27,835
SublocadeBuprenorphine12$25,194
Buprenorphine92$23,696
Oxycodone Hcl787$21,200
Xtampza ErOxycodone Myristate23$14,937
Oxymorphone Hcl ErOxymorphone Hcl13$10,380
LinzessLinaclotide11$9,803
MovantikNaloxegol Oxalate12$7,301
Fentanyl55$6,038
SuboxoneBuprenorphine Hcl/Naloxone Hcl11$5,830
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen211$4,721
Morphine Sulfate ErMorphine Sulfate156$4,160
Hydromorphone Hcl181$3,781
Pregabalin80$3,727

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Indivior Inc.Sublocade, Suboxone$15$31,02423 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 294 pain medicine providers in Pennsylvania.

Other pain medicine in Paoli

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →